Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
relapsed
.
Show all posts
Showing posts with label
relapsed
.
Show all posts
Saturday, September 28, 2024
FDA Grants Accelerated Approval for Ojemda (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma
›
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to deve...
Friday, March 1, 2024
FDA Approves Jaypirca (pirtobrutinib) for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma
›
Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), announced the U.S. Food and Drug Administration (FDA) approved Jaypirc...
Monday, February 22, 2016
Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma
›
In continuation of my update on Ibrutinib and Temsirolimus Temsirolimus Phase III trial findings suggest that patients with relap...
Wednesday, February 10, 2016
Role for carfilzomib in relapsed, refractory multiple myeloma treatment
›
In continuation of my update on carfilzomib Carfilzomib significantly improves outcomes in previously treated patients with relap...
›
Home
View web version
